Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Current reporting indicates that Andy Plump, the president of research and development at Takeda Pharmaceutical Co Ltd, has announced a planned retirement. According to coverage from TradingView, this departure is scheduled to become effective in June of 2027. BioPharma Dive describes Plump as the architect behind a significant R&D overhaul at the organization. BioSpace and Fierce Biotech similarly frame the exit as taking place in the wake of major pipeline reorganization and pipeline successes, marking a notable leadership transition for the enterprise. Various specialized industry outlets are tracking the announcement.

Coverage across these publications highlights Plump's long-term tenure heading the research and development division. Endpoints News notes the retirement alongside news of an unrelated appointment at Novo Nordisk, though the primary focus across the board remains on Plump's impending departure from Takeda. This transition arrives following a period of substantial structural and developmental change within the company. BioPharma Dive and BioSpace emphasize that Plump's tenure involved leading a comprehensive overhaul of the R&D division and reorganizing the product pipeline. Fierce Biotech connects the retirement directly to the successes achieved during this pipeline reorganization process.

The coverage does not yet specify who will permanently succeed Plump in the role or how the company plans to structure the leadership team closer to the effective date in June 2027. Observers and industry stakeholders will likely monitor future announcements from Takeda regarding succession plans for the R&D leadership position. While TradingView establishes the specific timeline for the exit, ongoing reporting will need to determine how the organization manages the handover of its restructured research pipeline. Coverage does not currently provide further details on Plump's future plans following the completion of his tenure, leaving the focus entirely on the upcoming transition period.